Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Esteve Trias"'
Autor:
Maria Castella, Anna Boronat, Raquel Martín-Ibáñez, Vanina Rodríguez, Guillermo Suñé, Miguel Caballero, Berta Marzal, Lorena Pérez-Amill, Beatriz Martín-Antonio, Julio Castaño, Clara Bueno, Olga Balagué, Europa Azucena González-Navarro, Carles Serra-Pages, Pablo Engel, Ramon Vilella, Daniel Benitez-Ribas, Valentín Ortiz-Maldonado, Joan Cid, Jaime Tabera, Josep M. Canals, Miquel Lozano, Tycho Baumann, Anna Vilarrodona, Esteve Trias, Elías Campo, Pablo Menendez, Álvaro Urbano-Ispizua, Jordi Yagüe, Patricia Pérez-Galán, Susana Rives, Julio Delgado, Manel Juan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss , Pp 134-144 (2019)
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to o
Externí odkaz:
https://doaj.org/article/0991d78034c649d5800886f6bf312afe
Autor:
Maria Castella, Miguel Caballero-Baños, Valentín Ortiz-Maldonado, Europa Azucena González-Navarro, Guillermo Suñé, Asier Antoñana-Vidósola, Anna Boronat, Berta Marzal, Lucía Millán, Beatriz Martín-Antonio, Joan Cid, Miquel Lozano, Enric García, Jaime Tabera, Esteve Trias, Unai Perpiña, Josep Ma Canals, Tycho Baumann, Daniel Benítez-Ribas, Elías Campo, Jordi Yagüe, Álvaro Urbano-Ispizua, Susana Rives, Julio Delgado, Manel Juan
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in
Externí odkaz:
https://doaj.org/article/c4affb1899c8444da99e673d6cca6b80
Autor:
Anna Duarri, Eduardo Rodríguez-Bocanegra, Gema Martínez-Navarrete, Marc Biarnés, Miriam García, Lucía Lee Ferraro, Bernd Kuebler, Begoña Aran, Elisabeth Izquierdo, Eli Aguilera-Xiol, Ricardo P. Casaroli-Marano, Esteve Trias, Eduardo Fernandez, Ángel Raya, Anna Veiga, Jordi Monés
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10497 (2021)
Background: The aim of this study was to test the feasibility and safety of subretinal transplantation of human induced pluripotent stem cell (hiPSC)-derived retinal pigment epithelium (RPE) cells into the healthy margins and within areas of degenera
Externí odkaz:
https://doaj.org/article/e70a59d39a364ec99dfd184537381747
Autor:
Esteve Trias, 1, Martine Nijs, 2, 3 4, Ioana Adina Rugescu, Francesco Lombardo, 5, Gueorgui Nikolov, 5, Veerle Provoost, 6, Annelies Tolpe, 7, Nathalie Vermeulen, 8, Zdravka Veleva, 9, Rita Piteira 10, Ricardo Casaroli-Marano 10, Kelly Tilleman, 7, EuroGTP II Study Group:EuroGTP II Study Group: Anna Vilarrodona, A Rita Piteira, Elba, Agustí, Elisabet, Tahull, Esteve, Trias, Eva Maria Martinez, Ivan, Miranda, Jaime, Tabera, Maria Luisa Perez, Marta, Torrabadella, Nausica, Otero, Oscar, Fariñas, Patricia, López-Chicón, Sergi, Querol, Ricardo, Casaroli, Akila, Chandrasekar, Kyle, Bennett, Paul, Rooney, Richard, Lomas, Mar, Carmona, Esteban, Molano, Myriam, Ormeño, Branka Golubić Ćepulić, Ivan, Rozman, Marijana, Dragović, Cristina, Pintus, Eliana, Porta, Fiorenza, Bariani, Letizia, Lombardini, Liliam, Santilli, Mariapia, Mariani, Paola Di Ciaccio, Silvia, Pisanu, Artur, Kamiński, Izabela, Uhrynowska-Tyszkiewicz, Ewa, Olender, Anne Marie van Walraven, Arlinke, Bokhorst, Ingrid van Veen, Kelly, Tilleman, Tolpe, Annelies, Veerle, Provoost, Lieve, Nuytinck, Maryana, Simeonova, Daniela, Staneva-Petkova, Dessislava, Tzoneva, Tsvetelina, Kircheva-Nikolova, Violetta, Marinkova, Valery, Georgiev, Yoran, Peev, Elizabeth, Manova, Cecilia, Surján, Éva, Belicza, Gábor, Szarvas, Judit, Lám, László, Bencze, Martin, Börgel, Mareike, Derks, Sibylla, Schwarz, Ramadan, Jashari, Richard, N Noumanje, Rosario Daiz Rodriguez, Tiia, Tallinen, Hanna, Kankkonen, Toni-Karri, Pakarinen, Gilbert, Verbeken, Jean-Paul, Pirnay, Thomas, Rose, Jean-Pierre, Draye, Simone, Hennerbichler, Jill, Davies, Jacinto, Ibañez, Cristina, Magli, Nathalie, Vermeulen, Monserrat, Boada, Eoin, Mcgrath, John, Armitage, Gary, Jones, Marta, Fraga, Dulce, Roldao, Josefina, Oliveira, Adolfo, Paolin, Diletta, Trojan, Giulia, Montagner, Diego, Ponzin, Stefano, Ferrari, Lombardo, Francesco, Carlijn, Voermans, Nelleke, Richters, Ioana Adina Rugescu, Gianpaolo, Azzena, Fabozzo, Assunta, Helene, Schoenmans, Jose Luis Pomar, Pablo, Gelber, Katalin, Rajczy, Boris, Calmels, Stephan, Mielke, Tanja, Netelenbos, Mirko, Ragazzo, Gueorgui, Nikolov, Marton, Elisabetta, Martine, Nijs, Antonella, Franch, Gianluca, Piovan, Francesco, Dell'Antonia, Martyn, Snow, Ines, Bojanic, Zdravka, Veleva, Grezgorz, Basak, Margarida, Amil, Sandra, Shaw, Aurora, Navarro, Tim, Spalding, Peter, Verdonk
Publikováno v:
HUMAN REPRODUCTION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
STUDY QUESTIONCan risks associated with novelties in assisted reproduction technologies (ARTs) be assessed in a systematic and structured way?SUMMARY ANSWERAn ART-specific risk assessment tool has been developed to assess the risks associated with th
Autor:
Miquel Lozano, Iolanda Jordan, Enric Garcia-Rey, Manel Juan, Miguel Caballero-Baños, Laia Guardia, Pedro Castro, E. Azucena González, Andrea Scalise, Eva Giné, Jordi Esteve, Ferran Torres, Neus Villamor, Esteve Trias, Alvaro Urbano-Ispizua, Marina Díaz-Beyá, Julio Delgado, Cristina Llanos, Sara Fernández, Unai Perpiñá, Josep M. Canals, Marta Español-Rego, Montserrat Torrebadell, Federico Ramos, Sara Varea, Mercedes Montoro, Tycho Baumann, Joan Cid, Anna Alonso-Saladrigues, M. Castella, Joaquín Sáez-Peñataro, Gonzalo Calvo, Valentín Ortiz-Maldonado, Susana Rives, Daniel Benitez-Ribas, Laia Alsina, Albert Català, Anna Faura, Nela Klein-González, Guillermo Suñe
Publikováno v:
Molecular Therapy. 29:636-644
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001
Autor:
Valentín Ortiz-Maldonado, Susana Rives, Marta Español-Rego, Anna Alonso-Saladrigues, Mercedes Montoro, Laura Magnano, Eva Giné, Mariona Pascal, Marina Díaz-Beyá, Maria Castella, Albert Català, Anna Faura, Luis Gerardo Rodríguez-Lobato, Aina Oliver-Caldes, Alexandra Martínez-Roca, Montserrat Rovira, E Azucena González-Navarro, Juan Ramón Ortega, Joan Cid, Miquel Lozano, Enric Garcia-Rey, Sara Fernández, Pedro Castro, Iolanda Jordan, Neus Villamor, Marta Aymerich, Montserrat Torrebadell, Àngela Deyà, Carlos Fernández de Larrea, Daniel Benitez-Ribas, Esteve Trias, Sara Varea, Gonzalo Calvo, Jordi Esteve, Alvaro Urbano-Ispizua, Manel Juan, Julio Delgado
Publikováno v:
Journal for Immunotherapy of Cancer
The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or b
Publikováno v:
Human gene therapy. 32(19-20)
The hospital exemption (HE) allows for the use of advanced therapy medicinal products (ATMPs) next to marketing authorization (MA), but under special conditions. The HE is only applicable to individual patients treated in the hospital setting and it
Publikováno v:
Bone marrow transplantation. 57(2)
In February 2021, the ‘Advanced Therapy Medicinal Product’ (ATMP) ARI-0001 (CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) under the ‘ho
Autor:
Esteve, Trias, Richard, Lomas, Jaime, Tabera, RITA PITEIRA, A., Kelly, Tilleman, CASAROLI-MARANO, RICARDO P., and AKILA CHANDRASEKAR, ON BEHALF OF EUROGTP II STUDY GROUP, Marton, Elisabetta
Publikováno v:
International Journal for Quality in Health Care. 32:80-84
A systematic methodology, able to assess risk and predict clinical safety and efficacy of Substances of Human Origin’ (SoHO) has been developed. The model consists of a risk based approach taking into account factors such as novelty of the product,
Publikováno v:
Cryobiology
We aimed to assess the feasibility of passive slow freezing (PSF using Mr. Frosty container, Nalgene) as an alternative to controlled slow rate freezing (CSF using (FreezalTM, Air liquide)) for human ovarian tissue (OT) cryopreservation. Validation s